Literature DB >> 25619668

Outcomes of phacoemulsification in patients with chronic ocular graft-versus-host disease.

Ujwala S Saboo1, Francisco Amparo, Hasanain Shikari, Ula V Jurkunas, Reza Dana.   

Abstract

PURPOSE: The purpose of this study was to evaluate the outcomes of phacoemulsification in patients with ocular graft-versus-host disease (GVHD).
METHODS: The occurrence of cataracts, cataract surgery, and its outcomes were analyzed in the medical records of 229 patients (458 eyes) with ocular GVHD. Outcome measures included pre- and postoperative corrected distance visual acuity (CDVA) and the rate of postoperative complications.
RESULTS: Of the 458 eyes evaluated, 58 were pseudophakic; from the 400 phakic eyes, 238 (59 %) presented with cataracts and 62 (26 %) underwent cataract surgery. Analysis of postoperative complications and visual outcomes at 1 month was performed in 51 eyes in which detailed surgical and immediate postoperative records were available. Preoperatively, the mean CDVA was 0.67 ± 0.57 LogMAR (Snellen 20/93), improving postoperatively to 0.17 ± 0.18 (Snellen 20/29) at 1 month (P < 0.0001), and to 0.13 ± 0.14 (Snellen 20/26) by the final follow-up visit (P < 0.0001). Postoperative complications included corneal epithelial defects (8 %), filamentary keratitis (6 %), worsening of corneal epitheliopathy (16 %), posterior capsular opacification (18 %), and cystoid macular edema (4 %). A corrected distance visual acuity of 20/30 or better was achieved in 87 % of the eyes; suboptimal CDVA improvement was attributable to severe ocular surface disease, pre-existing advanced glaucoma, and prior macular surgery.
CONCLUSIONS: Phacoemulsification in patients with chronic ocular GVHD is a safe and efficacious procedure resulting in significant visual improvement. Overall, postoperative adverse events responded well to timely management.

Entities:  

Mesh:

Year:  2015        PMID: 25619668      PMCID: PMC4447562          DOI: 10.1007/s00417-015-2940-3

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN: 0721-832X            Impact factor:   3.117


  37 in total

1.  Posterior capsule opacification in eyes with steroid-induced cataracts: Comparison of early results.

Authors:  Mamidipudi R Praveen; Gauri D Shah; Abhay R Vasavada; Alpesh R Shah; Kaid Johar; Yogesh Gami; Rasesh P Diwan; Shubhangi M Shah
Journal:  J Cataract Refract Surg       Date:  2011-01       Impact factor: 3.351

Review 2.  Ocular graft-versus-host disease: a review.

Authors:  Hasanain Shikari; Joseph H Antin; Reza Dana
Journal:  Surv Ophthalmol       Date:  2013-03-27       Impact factor: 6.048

Review 3.  Ocular graft-versus-host disease.

Authors:  Michelle Hessen; Esen K Akpek
Journal:  Curr Opin Allergy Clin Immunol       Date:  2012-10

4.  Impact of GvHD on quality of life in long-term survivors of haematopoietic transplantation.

Authors:  S Pallua; J Giesinger; A Oberguggenberger; G Kemmler; D Nachbaur; J Clausen; M Kopp; B Sperner-Unterweger; B Holzner
Journal:  Bone Marrow Transplant       Date:  2010-03-15       Impact factor: 5.483

5.  Visual acuity and anterior segment findings in chronic graft-versus-host disease.

Authors:  Evan J Allan; Mary E D Flowers; Michelle P Lin; Richard E Bensinger; Paul J Martin; Michael C Wu
Journal:  Cornea       Date:  2011-12       Impact factor: 2.651

6.  Sensitivity change in cornea and tear layer due to incision difference on cataract surgery with either manual small-incision cataract surgery or phacoemulsification.

Authors:  Ratna Sitompul; Grace S Sancoyo; Johan A Hutauruk; Tjahjono D Gondhowiardjo
Journal:  Cornea       Date:  2008-09       Impact factor: 2.651

7.  Impact of ocular graft-versus-host disease on visual quality of life in patients after allogeneic stem cell transplantation: questionnaire study.

Authors:  Anjo Riemens; Liane C J Te Boome; Viera Kalinina Ayuso; Jonas J W Kuiper; Saskia M Imhof; Henk M Lokhorst; Rothova Aniki
Journal:  Acta Ophthalmol       Date:  2013-04-22       Impact factor: 3.761

8.  Investigation of dry eye disease and analysis of the pathogenic factors in patients after cataract surgery.

Authors:  Xue-Min Li; Lizhong Hu; Jinping Hu; Wei Wang
Journal:  Cornea       Date:  2007-10       Impact factor: 2.651

9.  Contamination risk of 100% autologous serum eye drops in management of ocular surface diseases.

Authors:  Onsiri Thanathanee; Warachaya Phanphruk; Orapin Anutarapongpan; Amornrat Romphruk; Olan Suwan-Apichon
Journal:  Cornea       Date:  2013-08       Impact factor: 2.651

10.  Incidence and pattern of dry eye after cataract surgery.

Authors:  Ngamjit Kasetsuwan; Vannarut Satitpitakul; Theerapa Changul; Supharat Jariyakosol
Journal:  PLoS One       Date:  2013-11-12       Impact factor: 3.240

View more
  5 in total

Review 1.  [Ocular graft versus host disease : Corneal complications].

Authors:  H Westekemper; S L Scholz; H Thomasen; C Halfwassen; K-P Steuhl
Journal:  Ophthalmologe       Date:  2017-08       Impact factor: 1.059

2.  [Ocular graft-versus-host disease].

Authors:  T Dietrich-Ntoukas; P Steven
Journal:  Ophthalmologe       Date:  2015-12       Impact factor: 1.059

Review 3.  Update on ocular graft-versus-host disease.

Authors:  Sridevi Nair; Murugesan Vanathi; Ritika Mukhija; Radhika Tandon; Sandeep Jain; Yoko Ogawa
Journal:  Indian J Ophthalmol       Date:  2021-05       Impact factor: 1.848

4.  Outcomes and complications of cataract surgery in patients with chronic ocular graft-versus-host-disease-a multicenter, retrospective analysis.

Authors:  Uta Gehlsen; Christiane Faust; Christiane Blecha; Tina Dietrich-Ntoukas; Philipp Eberwein; Susanne Issleib; Tobias Meyer-Ter-Vehn; Regine Braun; Henrike Westekemper; Philipp Steven
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2022-03-07       Impact factor: 3.535

5.  Novel Method to Determine Target Refraction in Cataract Surgery for Patients Dependent on Therapeutic Scleral Lenses.

Authors:  Kevin K Ma; Zhonghui K Luo
Journal:  Eye Contact Lens       Date:  2021-06-01       Impact factor: 3.152

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.